Journal · Industry & Trends
Some years bring new products. A few change the direction of an entire field. 2026 was one of those years for aesthetic medicine. Here is what changed, and why we do not think it will change back.
For the first time, a therapy designed to reverse part of the ageing process at the cellular level was given to human patients. ER-100, based on David Sinclair’s epigenetic reprogramming research, began its first trial in people with optic nerve disease, and early safety data was released in October. It is far from proven, but it marked a cultural turning point: “reversing ageing” moved from marketing slogan to clinical endpoint. Read our ER-100 explainer.
GLP-1 medicines became even more accessible, with oral options for weight management authorised in the UK during the year. Clinics now see a growing population of patients going through rapid facial and body change, needing skin quality, structure and laxity treatment rather than simple volume. See GLP-1s in 2026.
Polynucleotides, PDRN, exosomes and biostimulators were once niche. In 2026 they became the treatments patients asked for by name. Our own catalogue reflects it: Regenerative & Longevity and Skin Boosters are now among the largest categories we carry.
The backlash against overfilled faces turned into a clear standard. Patients want to look rested and healthy, not “done”. Practitioners responded with lower volumes, better placement and more combination treatment.
Regulation is still a work in progress, so precision matters:
The direction is unmistakable: more accountability, more training and more focus on safe premises. Clinics that prepare early will benefit.
Patients started asking about NAD+, biological age and healthspan in the same breath as skin boosters. Aesthetic clinics are becoming a front door to preventive health. Read our NAD+ guide.
2026 did not just add new treatments. It changed what patients believe aesthetic medicine is for.
Each of these shifts is driven by something durable: better science, a permanently changed patient population, rising patient sophistication and incoming regulation. None of them is a fad. Together they move aesthetics from a corrective discipline to a regenerative, preventive one.
Stock the categories driving the change.
Not yet. The legal power exists, but the regulations, procedure lists and start date have not been finalised as of November 2026.
Regenerative aesthetics, led by polynucleotides, skin boosters and biostimulators, alongside the growing impact of GLP-1 weight loss.
Sources: Health and Care Act 2022, section 180; Botulinum Toxin and Cosmetic Fillers (Children) Act 2021; UK Government consultation response on non-surgical cosmetic licensing (2025); Life Biosciences ER-100 updates (2026).
Keep reading
Immortality is not on the horizon. But for the first time, therapies designed to slow or reverse parts of ageing are being tested in people. Here is what is real, what is hype and what it means for aesthetics.
In 2026 a therapy built on David Sinclair's epigenetic reprogramming research was given to people for the first time, in an attempt to restore sight lost to glaucoma and optic nerve stroke. Here is what the early data shows.
Oral GLP-1 tablets, higher-dose injections and millions of new patients. How the GLP-1 revolution moved on in 2026, and why it is reshaping aesthetic practice.
